Abstract: The invention describes a prophylactic treatment of cerebral ischemia with CDP-Choline in patients who have undergone major surgery or are at risk of suffering an acute ischemic event.

Abstract: The invention relates to R-(?)-1-[2-(7-Chloro-benzo[b]thiophen-3-yl-methoxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole and the salts thereof. The invention also relates to compositions thereof and their use either for treating fungal infections in humans and animals or combating crop diseases. A process for their preparation is also described.

Abstract: The process consists in condensing (2-methyl-6,7,8,9-tetrahydro-4 H-pyrido-[1,2-a]pyrimidin-3-yl)-acetaldehyd with 6-fluoro-3-piperidinyl)-1,2-benzisoxazole to yield the intermediate enamine, 3-{2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]vinyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2,-a]pyrimidin-4 -one followed by reduction of such an enamine.

Abstract: The invention describes a prophylactic treatment of cerebral ischemia with CDP-Choline in patients who have undergone major surgery or are at risk of suffering an acute ischemic event.

Abstract: The invention describes the prophylactic treatment of cerebral ischemia with CDP-Choline in patients who have undergone major surgery or are at risk of suffering an acute ischemic event.

Abstract: The process consists in condensing (2-methyl-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]pyrimidin-3-yl)-acetaldehyde with 6-fluoro-3-piperidinyl)-1,2-benzisoxazole to yield the intermediate enamine, 3-{2-[4-(6-fluorobenzo[d]isoxazole-3-yl)-piperidin-1-yl]vinyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2,-a]pyrimidin-4-one followed by reduction of such an enamine.

Abstract: The invention relates to the use of CDP-Choline or its pharmaceutically acceptable salts for the preparation of a medicinal product for the treatment of alcohol withdrawal syndrome at daily doses equivalent to 0.5-2 g of free CDP-Choline.

Abstract: The present invention relates to a process for preparing (±)-trans-4-p-fluorophenyl-3-hyroxymethyl-1-methylpiperdine of formula (I). The present invention also relates to novel intermediates of the formula (IX) and (IX?) methods for preparing said intermediates and the use of said compounds for preparing Paroxetine and Omiloxetine.

Abstract: The invention relates to R-(?)-1-[2-(7-Chloro-benzo[b]thiophen-3-yl-methoxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole and the salts thereof. The invention also relates to compositions thereof and their use either for treating fungal infections in humans and animals or combating crop diseases. A process for their preparation is also described.

Abstract: The present invention relates to a process for preparing (±)-trans-4-p-fluorophenyl-3-hyroxymethyl-1-methylpiperdine of formula (I). The present invention also relates to novel intermediates of the formula (IX) and (IX′) methods for preparing said intermediates and the use of said compounds for preparing Paroxetine and Omiloxetine.

Abstract: The invention relates to the use of CDP-Choline or its pharmaceutically acceptable salts for the preparation of a medicinal product for the treatment of alcohol withdrawal syndrome at daily doses equivalent to 0.5-2 g of free CDP-Choline.

Abstract: The invention describes the prophylactic treatment of cerebral ischemia with CDP-Choline in patients who have undergone major surgery or are at risk of suffering an acute ischemic event.

Abstract: 3-(Hydroxymethyl)chromen-4-ones of formula (I) are described and a process for preparing said compounds.

Abstract: 7-[3-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]propoxy]-chromen-4-one derivatives having the formula (I): wherein R is hydrogen, CHO, CH2OR2 or COOH; R1 is hydrogen or CH2OH; and R2 is alkyl having 1 to 4 carbon atoms with the proviso that one of substituents R and R1 should be hydrogen, as well as their pharmaceutically acceptable salts. The process for their preparation and the pharmaceutical compositions containing them are also described. The compounds are new and are useful in the treatment of psychosis, schizophrenia and allergy.

Abstract: Two forms of N-[[[2-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]ethyl]amino] methylene]-4-bromo-benzenesulfonamidehave been identified. A process for the preparation of thereof and the use thereof are described.

Abstract: The process consists of reacting (-)trans-N-p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperid ine acetate with 2-chloro- or 2-bromo-4'-fluoroacetophenone. The resulting compound can be isolated as a pharmaceutically acceptable addition salt by reaction with the corresponding acid.

Abstract: Two polymorphs of 1-?2,4-dichloro-.beta.-?(7-chloro-benzo?b!thien-3-yl)methoxy!phenetyl!imid azole mononitrate have been identified. A process for the preparation thereof and composition are described.

Abstract: Polymorph B of (1-diphenylmethyl)-4-?3-(2-phenyl-1,3-dioxolan-2-yl)propyl!piperazine have been identified. A process for its preparation and its use are described.

Abstract: The present invention relates to new 5H-thiazolo?3,2-a!pyrimidin -5-one derivatives having the formula (I): ##STR1## wherein Ar is phenyl optionally substituted by one or two groups selected from halogen, alkyl having from 1 to 4 carbon atoms, methylendioxy, alkoxy having from 1 to 4 carbon atoms, and trifluoromethyl; and R is a group selected from (a) or (b): ##STR2## as well as their pharmaceutically acceptable addition salts, which are useful in the treatment of psychosis, schizophrenia and anxiety. This invention also discloses methods and intermediates for their preparation and pharmaceutical compositions containing them.

Abstract: The present invention relates to 4-(6-fluoro-1,2-benzisoxazolyl)-1-piperidinyl-propoxy-chromen-4-one derivatives having the formula (I): ##STR1## wherein R is hydrogen or alkyl having 1 to 4 carbon atoms optionally substituted by hydroxyl, as well as their pharmaceutically acceptable addition salts, which are useful in the treatment of psychosis, schizophrenia and anxiety.